The primary therapeutic role of Meldonium is to provide supportive benefits across clinical domains characterized by symptoms linked to organ-specific functional stress. It is considered relevant for addressing conditions that involve symptomatic stress and disruptive manifestations that interfere with functional stability.

The medication is commonly used in situations involving certain distressing symptoms across several therapeutic areas, including stable angina pectoris, chronic heart failure, and disorders of brain circulation. It helps address symptom clusters related to physical discomfort, such as chest pain and noticeable physical fatigue during exertion.

“The primary benefit is supporting patients during difficult episodes, assisting with maintaining functional stability, and improving day-to-day comfort.”

This application offers symptomatic relief that supports patients during difficult episodes, aiming to ease the overall symptom load. Meldonium may be part of symptomatic management in specific scenarios, such as addressing generalized weakness (asthenia) and persistent dizziness in cerebrovascular disorders, or managing vascular deficits in conditions like diabetic retinopathies.

---

Quick Fact: Relief for Physical Discomfort

Area of Use	Symptom/Strain Addressed	Benefit Provided
Cardiovascular	Chest pain, exertional fatigue	Contributes to support for comfort and physical capacity.
Cerebrovascular	Dizziness, asthenia (weakness)	Assists with maintaining functional stability and well-being.
Vascular Deficits	Organ-specific functional stress	Provides support that helps ease the overall symptom burden.

The official regulatory profile for Мельдоний strictly defines the patient populations permitted to use the medicine, establishing multiple absolute prohibitions and mandatory cautions.

Absolute Contraindications

Use is prohibited for individuals with known hypersensitivity to the substance and those diagnosed with increased intracranial pressure, including cases related to tumors or impaired venous outflow. The medicine is also contraindicated in patients with severe hepatic and/or renal insufficiency/failure due to a lack of established safety data.

Age and Physiological Restrictions

Мельдоний is not recommended for the entire pediatric and adolescent population (under 18 years), as safety and efficacy have not been established. Use is also not recommended during pregnancy and the breastfeeding/lactation period.

Conditional Use and Caution

The regulatory label requires caution when the medicine is used in patients with chronic liver and kidney diseases of mild to moderate severity. While older adults are generally permitted to use the medicine, the presence of organ impairment in this group may require special consideration.

Interactions with other medicines and products

The official regulatory profile for Мельдоний focuses primarily on pharmacodynamic interactions with specific cardiovascular medicines. All factual statements are based strictly on authoritative government regulatory documentation.

Pharmacodynamic Potentiation

Co-administration with certain products may lead to an intensification of action. This effect is documented for several classes and specific substances, reflecting an additive effect rather than an alteration of drug concentration. Medicinal products with documented interaction potential include:

• Hypotensive agents: Drugs used to reduce blood pressure.
• Peripheral Vasodilators
• Beta-adrenoblockers
• Nitrates: Co-use with Glyceryl trinitrate may result in intensified effects.
• Calcium Channel Blockers: Such as Nifedipine.

Due to this potential for action intensification, co-use with these agents requires consideration. However, Мельдоний may be used alongside other cardiovascular medicines, including antiarrhythmics, anticoagulants, and diuretics, as per the established regulatory context.

Pharmacokinetic and Other Interactions

Official sources state that there is no published information on the metabolism of Мельдоний in humans. Consequently, specific enzyme-mediated interactions (such as those involving CYP enzymes) or transporter-based interactions are not formally defined in the prescribing information. Furthermore, no substances are explicitly labeled as contraindicated combinations in the official interaction section.

How Мельдоний Works: Mechanism of Action

Мельдоний (Meldonium) acts as a metabolic modulator by targeting the L-carnitine biosynthetic pathway. Its primary action is the competitive inhibition of the enzyme gamma-Butyrobetaine Hydroxylase (GBBH). This inhibition restricts the final step of L-carnitine synthesis, reducing its concentration within cells. Lowered L-carnitine availability limits the transport of long-chain fatty acids into the mitochondria, suppressing Fatty Acid beta-oxidation (FAO). This causes the cell to shift its fuel source preference to the more oxygen-efficient Glucose Oxidation for ATP production, which results in sustained cellular ATP production under conditions of reduced oxygen availability. This fuel shift simultaneously reduces the accumulation of cytotoxic acyl-CoA intermediates that correlate with disruption of cellular integrity. A secondary cascade involves the accumulation of the precursor gamma-butyrobetaine (GBB), which enhances the synthesis and release of Nitric Oxide (NO) from the vascular endothelium. Increased NO promotes vasodilation, resulting in augmented regional blood perfusion to metabolically active tissues.

The use of Мельдоний (Meldonium) follows specific administration protocols, utilizing its availability as hard capsules for oral use and a sterile solution for intravenous (IV) injection. The injection solution is generally reserved for initiating an acute treatment phase, followed by a transition to the oral form for maintenance.

The standard adult daily dose is between 500 mg and 1000 mg of meldonium dihydrate, with 1000 mg defined as the maximum recommended daily dose. This is usually administered once daily; however, a 1000 mg dose may be divided into two single doses. To prevent a potential stimulating effect, it is advised to take the medicine in the morning. Oral capsules should be swallowed whole with water and may be taken with food to avoid gastrointestinal disturbances.

Treatment is typically administered in time-bound courses or cycles lasting from 4 to 6 weeks. The intravenous administration phase, if used, is generally short-term before the switch to the oral form. Regarding specific populations, the medicine is not recommended for use in children and adolescents under 18 years due to insufficient data. Caution is advised when administering the drug to patients with existing renal or hepatic disorders. If a dose is missed, patients are instructed not to take a double dose to make up for it, thereby ensuring that the maximum daily dosage is not exceeded.

Evidence for use in Cardiovascular Conditions

Research has explored Мельдоний, as it was studied for heart-related issues, such as angina pectoris (chest pain caused by reduced blood flow to the heart) and chronic heart failure. Studies have been conducted to observe how research examined outcomes related to heart function, circulation, and outcomes reflecting daily functioning or activity level in these patient groups.

For individuals with angina, studies have examined outcomes reflecting daily functioning or activity level, particularly how well patients could engage in activity without developing symptoms. These findings describe patterns observed in the studies where some patients reported perceived discomfort less frequently, and patterns related to maintaining activity level were observed in the studies over the short-term study period. Comparative evidence against a full range of established treatments is sometimes lacking.

Evidence for use in Cerebrovascular and Neurological Conditions

Мельдоний has been evaluated in studies examining conditions associated with acute or disruptive episodes, specifically issues involving brain circulation problems and the time following events like ischemic stroke. The research explored short-term symptom changes in these observed populations, particularly outcomes related to systemic or functional imbalance following the acute phase. Findings help contextualize how patients reported their perceived discomfort and outcomes reflecting daily functioning or activity level. Follow-up durations were limited in many of these studies, meaning data are still emerging.

Long-term Studies and Follow-up

Understanding the sustained effects over time is crucial. Studies exploring short-term symptom changes in relation to Мельдоний often have limited follow-up durations. Therefore, there is limited information for long-term outcomes. The evidence related to the durability of a therapeutic response—how long any measured changes last—is not fully established. While findings describe patterns observed in the studies, data for long-term outcomes remain insufficient.

What is Still Uncertain about Мельдоний

The body of research on Мельдоний, while available in certain areas, has several important evidence gaps. One key area of uncertainty relates to the consistency of findings, leading to mixed findings, and more research is needed to fully understand them. Research provides context but not individual predictions, and the evidence base often consists of studies where follow-up durations were limited. Overall, the evidence contributes to the broader evidence landscape but clarifies that data are still emerging in several key areas.

Key Studies & References

1. Application of Mildronate in the treatment of coronary heart disease: a systematic review and meta-analysis
2. Meldonium for the treatment of stable angina: a systematic review and meta-analysis of randomized controlled trials

Common questions about Мельдоний (FAQ)

Q: Is there a link between Мельдоний and sleep problems?

Official product information advises that this medicine is advised to be taken during the first half of the day. This practice is recommended to help prevent a potential stimulating effect that could interfere with nighttime rest. The side effect profile also lists Agitation under Nervous System Disorders, though its frequency of occurrence is not known.

Q: Do food or certain diets change how Мельдоний is absorbed?

Regulatory guidance specifically addresses the administration of the oral capsules. The official product information indicates that the medicine may be taken with food. This approach is suggested to help minimize or avoid potential gastrointestinal disturbances.

Q: How long is a typical course of treatment with Мельдоний?

According to the official regulatory protocols for this medicine, the administration is managed in time-bound treatment courses or cycles. A common duration for these courses is described as lasting approximately four to six weeks.

Q: How does the use of Мельдоний affect patients with stable angina?

Studies examining the use of the medicine have included individuals with stable angina (a type of chest pain). Findings describe patterns observed in studies where some patients reported perceived discomfort less frequently, and patterns related to maintaining activity level were observed in the studies over the short-term study period. These findings help contextualize the medicine's use in cardiovascular conditions.

Q: Why is Мельдоний sometimes mentioned with sports performance?

The medicine is classified as a metabolic modulator and is currently included on the World Anti-Doping Agency's (WADA) Prohibited List. This prohibition is due to evidence suggesting it has been used by athletes, with the WADA classification being based on its metabolic modulator action.

Q: Are the studies on Мельдоний considered high-quality?

Official research overviews indicate that the evidence base for this medicine has several gaps, including mixed findings and studies where follow-up durations were limited. This which highlights that data for long-term outcomes remain insufficient.

Q: Is Мельдоний available over the counter in some places?

The medicine's status as a prescription-only drug depends entirely on the specific country's regulatory body. Official reports indicate that in some jurisdictions where Мельдоний is approved, such as Latvia, it has been available for purchase without a prescription.

Q: What is the typical expectation for the duration of the effect of Мельдоний after stopping treatment?

The long-term effects of the medicine and the durability of its response are a focus area in the existing research. Studies have noted that information regarding how long any measured changes or benefits last after a course of treatment is completed is not yet fully established. The available evidence is still emerging on this specific aspect.

Q: Is there a link between Мельдоний and anxiety or mood changes?

The official safety profile for the medicine includes several documented adverse reactions related to the nervous system. The term Agitation is listed as a potential effect in the safety documents, although its reported frequency is classified as 'Not Known'. No other terms related to general anxiety or mood changes are documented in the official list of adverse reactions.

Storage and Disposal of Meldonium

Official regulatory guidelines define specific conditions mandatory for storing Meldonium to maintain its stability and quality.

Mandatory Storage Conditions

Requirement	Specific Condition
Temperature Limit	Store at a temperature not above 25 C (seventy-seven degrees Fahrenheit).
Environmental Protection	Store in the original package to protect from moisture and light.
Container Integrity	The container must be kept tightly closed.
Child Safety	Keep the medicinal product out of the sight and reach of children.

Disposal Instructions

Unused or expired Meldonium product must be handled in accordance with local regulations for pharmaceutical waste. The product should not be disposed of via household waste or wastewater, ensuring environmentally safe handling as mandated by official disposal guidance.